Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Joel Mitnick comments on the Federal Trade Commission’s approval of Bristol-Myers Squibb’s $74 billion acquisition of Celgene and what the 3-2 party-line vote signals. https://www.cadwalader.com/news/recent-press/bristol-myers-buyout-of-celgene-approved-by-deeply-divided-ftc